We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesViaderma Inc

Viaderma Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
4099
Market Cap
0.25M
P/E
0.02

Momentum Score

…

ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as well as antifungal, cosmetics, and pain management products. In addition, company develops anti-aging skin care, pain management, hair-loss, and toenail fungus products. It also provides licenses for its technology for pharmaceutical industry in various therapeutic areas. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Las Vegas, Nevada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.01
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Viaderma Inc is an OTC Pink-listed company for which public filings and business descriptions are limited, so its core operations are not clearly documented in widely available sources. Because disclosures are sparse, major long-term growth drivers are not identifiable from public information, and investors may find small-cap exposure but should monitor filings and audited financials for clarity.

Key investment risks include lack of transparent disclosures and audited reporting, illiquid, volatile trading on the Pink market, thin capitalization and financing uncertainty, and governance and execution risks common to microcap OTC issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.04M
Revenue Per Share
-
Gross Profit TTM
0.04M
Debt / Equity
2.62
ROE
-
Net Debt
0.31M
ROCE
65.38%
Diluted EPS TTM
0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax 0.00M 0.59M -0.99M -0.43M -0.60M
Net income 0.00M 0.59M -0.99M -0.43M -0.60M
Gross profit 0.60M 0.54M 0.51M 0.01M 0.01M
Ebit 0.08M 0.69M -0.88M -0.28M -0.34M
Ebitda 0.08M 0.69M -0.88M -0.28M -0.34M
Depreciation and amortization 0.00M 0.00M 0.00M 0.00M 0.00M
Operating income 0.19M 0.25M 0.33M -0.07M -0.34M
Other operating expenses 0.42M 0.30M 0.19M 0.08M 0.35M
Interest expense 0.08M 0.10M 0.11M 0.15M 0.26M
Income tax expense 0.00M 0.00M 0.00M 0.00M 0.00M
Total revenue 0.60M 0.54M 0.51M 0.01M 0.01M
Total operating expenses 0.42M 0.30M 0.18M 0.08M 0.35M
Cost of revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total other income expense net -0.18M 0.35M -1.32M -0.36M -0.26M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1.28M 0.71M 0.28M 0.12M 0.07M
Intangible assets 0.00M 0.00M 0.00M 0.00M 0.00M
Total liab 1.16M 2.56M 2.71M 2.31M 3.07M
Total stockholder equity 0.12M -1.84M -2.44M -2.19M -3.00M
Other current liab 0.82M 2.13M 2.26M 1.69M 2.24M
Common stock 0.12M 0.10M 0.10M 0.09M 0.07M
Retained earnings -13.61M -13.61M -14.20M -11.89M -12.40M
Other assets - - - - 0.00M
Cash 0.01M 0.01M 0.01M 0.01M 0.01M
Total current liabilities 1.16M 2.56M 2.71M 2.31M 3.07M
Net debt 0.31M 0.41M 0.40M 0.58M 0.76M
Short term debt 0.32M 0.42M 0.42M 0.59M 0.77M
Short long term debt total 0.32M 0.42M 0.42M 0.59M 0.77M
Other stockholder equity 13.70M 11.74M 11.74M 9.67M 9.38M
Total current assets 1.28M 0.71M 0.27M 0.12M 0.07M
Net receivables 1.27M 0.70M 0.26M 0.03M 0.02M
Inventory - - - 0.08M 0.04M
Accounts payable 0.02M 0.01M 0.03M 0.03M 0.05M
Accumulated other comprehensive income -0.12M -0.10M -0.10M -0.09M -0.07M
Non currrent assets other 0.00M 0.00M 0.00M 0.00M 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total cash from financing activities - - - 0.01M 0.01M
Net income 0.00M -0.08M -0.26M -0.35M -0.60M
Change in cash 0.00M -0.00M 0.00M 0.00M -0.00M
Begin period cash flow 0.01M 0.01M 0.01M 0.01M 0.01M
End period cash flow 0.01M 0.01M 0.01M 0.01M 0.01M
Total cash from operating activities 0.00M -0.00M 0.00M -0.01M -0.02M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory - - 0.00M -0.04M -0.04M
Change to account receivables -0.60M -0.44M -0.23M -0.01M 0.01M
Other cashflows from financing activities - - - 0.01M 0.01M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.35M -0.15M -0.30M 0.20M 0.28M
Other non cash items 0.34M 0.23M 0.56M 0.15M 0.31M
Free cash flow 0.00M -0.00M 0.00M -0.01M -0.02M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VDRM
Viaderma Inc		 -
-%		 0.00 0.02 - 5.52 0.00 0.35 0.90
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

Viaderma Inc

ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company's lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as well as antifungal, cosmetics, and pain management products. In addition, company develops anti-aging skin care, pain management, hair-loss, and toenail fungus products. It also provides licenses for its technology for pharmaceutical industry in various therapeutic areas. The company was formerly known as Décor Products International, Inc. and changed its name to ViaDerma, Inc. in May 2014. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Las Vegas, Nevada.

1050 E Flamingo Rd, Las Vegas, NV, United States, 89119

(800) 585 8685

https://viaderma.com

Name Title Year Born
Mr. Qing Hua Lin Chief Financial Officer and Director 1981
Mr. Baotang Zhao Chief Sales Officer 1978
Mr. Zhang Xie Corp. Sec. and Director 1979
Mr. Shaowen Zhang Mang. of Production 1973
Dr. Christopher A Otiko Founder, Chief Exec. Officer and Pres NA
Dr. Andrew Berman M.D., MPH Medical Director and Member of Advisory Board NA
Mr. Zhang Xie Corporate Secretary and Director 1979
Dr. Christopher A Otiko Founder, Chief Executive Officer and President NA
Dr. Andrew G. Berman M.D., MPH Medical Director and Member of Advisory Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…